NCT02310477 2026-03-13
REBECCA
Centre Oscar Lambret
Completed
Clinical Trials
19 trialsNCT06137170 2026-03-02
RegoSeq
Bayer
Completed
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT06321055 2025-05-20
An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
Bayer
Completed
NCT06029010 2025-02-26
COLONGER
Bayer
Completed
NCT04810182 2024-02-08
Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS
Istituto Oncologico Veneto IRCCS
Completed
NCT05594147 2023-11-07
ROCURS
Bayer
Completed
NCT02106858 2023-07-24
StivargaPMS
Bayer
Completed
NCT05942768 2023-07-12
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Hunan Cancer Hospital
Completed
NCT03289273 2023-06-13
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Bayer
Completed
NCT01933958 2022-04-01
Regorafenib Post-marketing Surveillance in Japan
Bayer
Completed
NCT03829852 2021-07-23
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
Taipei Veterans General Hospital, Taiwan
Completed
NCT03010722 2021-05-03
PROSPECT-R
Royal Marsden NHS Foundation Trust
Completed
NCT02347852 2018-09-10
REGO-ACT
Bayer
Completed
NCT01843400 2018-08-02
Regorafenib Post-marketing Surveillance
Bayer
Completed
NCT03386825 2018-05-15
COLONG
Bayer
Completed
NCT01959269 2018-03-08
RECORA
Bayer
Completed
NCT02656524 2018-02-12
Stivarga Real Life Evidence in Hungary
Bayer
Completed
NCT02042144 2018-01-16
Correlate
Bayer
Completed